Alzheimer Disease, Biomarkers, and Clinical Symptoms —Quo Vadis?—Reply

In Reply The Letter to the Editor by Montero-Odasso and colleagues addresses noncognitive manifestations of Alzheimer disease (AD). Their letter discusses a recent article from the Mayo Clinic. Using positron emission tomography biomarkers of amyloidosis (A) and tauopathy (T), the Mayo study examined the age- and sex-specific prevalence of 3 biologically defined entities: amyloidosis (A+) regardless of tau status, A+T −, and A+T+. We compared the age and sex specific prevalence of these 3 biomarker-defined entities with 3 clinical syndromes commonly associated with AD: clinically defined probable AD using the McKhann et al criteria, mild cognitive impairment, and dementia. We found that the prevalence of biolog ical AD (defined by the A+T+ biomarker profile) is more prevalent than the classic syndrome of clinically defined probable AD at all ages and roughly 3 times more prevalent at age 85 years in men and women. We attributed this to the fact that brain pathology precedes symptoms by years; thus, many in dividuals who have the disease do not have cognitive impairment.
Source: JAMA Neurology - Category: Neurology Source Type: research

Related Links:

In conclusion, in the absence of obesity, visceral adipose tissue possesses a pronounced anti-inflammatory phenotype during aging which is further enhanced by exercise. Methods of Inducing Cellular Damage are Rarely Relevant to Aging, and the Details Matter https://www.fightaging.org/archives/2019/08/methods-of-inducing-cellular-damage-are-rarely-relevant-to-aging-and-the-details-matter/ One of the major challenges in aging research is determining whether or not models of cellular or organismal damage and its consequences are in any way relevant to the natural processes of aging. One can hit a brick with...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
DiscussionOur results encourage an independent validation cohort study to confirm the indication that the plasma Aβ1–40/Aβ1–42 ratio, assessed via Simoa, may improve future standard of care and clinical trial design.
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - Category: Geriatrics Source Type: research
In this study, we report the age-associated differences between fetal MSC (fMSC) populations and MSCs isolated from elderly donors with respect to their transcriptomes. We successfully reprogrammed fMSCs (55 days post conception) and adult MSC (aMSC; 60-74 years) to iPSCs and, subsequently, generated the corresponding iMSCs. In addition, iMSCs were also derived from ESCs. The iMSCs were similar although not identical to primary MSCs. We unraveled a putative rejuvenation and aging gene expression signature. We show that iMSCs irrespective of donor age and cell type re-acquired a similar secretome to that of th...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Conclusions: Our results demonstrate that the presence and extent of cSS are associated with reduced CSF ß-amyloid 42 levels. Further studies are needed to investigate the underlying mechanisms of this association. Introduction Cerebral amyloid angiopathy (CAA)—characterized by the deposition of ß-amyloid in the walls of leptomeningeal vessels—is a common cerebral small vessel disease and a major cause of intracerebral hemorrhage in the elderly (1–3). Furthermore, it has become evident that CAA is associated with cognitive impairment (4). Specifically, it has been shown that CAA patien...
Source: Frontiers in Neurology - Category: Neurology Source Type: research
C2N Diagnostics is experiencing a couple of breakthroughs with its Alzheimer’s disease detection test - one courtesy of FDA. The agency, which is slowly rising back to full strength after the temporary government shutdown, granted the St. Louis-based company breakthrough device designation for a brain amyloidosis blood test. In addition, C2N said it is launching its Plasma Test for Amyloid Risk Screening (PARIS) Study that is evaluating and validating the clinical diagnostic performance of the C2N brain amyloidosis blood test. The company said the C2N test is a blood-based in vitro diagnostic being develo...
Source: MDDI - Category: Medical Devices Authors: Tags: IVD Source Type: news
ConclusionDisorders associated with early-life alterations in amyloid precursor protein production or processing are associated with a distinct pattern of early striatal fibrillary Aβ deposition before significant cognitive impairment. A better understanding of this unique pattern could identify important mechanisms of Aβ deposition and possibly important targets for early intervention.
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - Category: Geriatrics Source Type: research
DiscussionPET can evaluate amyloid expansion from cortex to subcortex. Using striatal signal as a marker of advanced amyloidosis may increase predictive power in Alzheimer's dementia research.
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - Category: Geriatrics Source Type: research
ConclusionDisorders associated with early-life alterations in amyloid precursor protein production or processing are associated with a distinct pattern of early striatal fibrillary Aβ deposition before significant cognitive impairment. A better understanding of this unique pattern could identify important mechanisms of Aβ deposition and possibly important targets for early intervention.
Source: Alzheimer's and Dementia: The Journal of the Alzheimer's Association - Category: Geriatrics Source Type: research
The use of PET scans to confirm the presence of dementia-inducing amyloid plaque...Read more on AuntMinnie.comRelated Reading: PET links amyloid, vascular factors to cognitive decline PET with novel tracers foretells early Alzheimer's risk PiB-PET study strengthens link between amyloid, dementia High amyloid levels on PET may indicate early Alzheimer's JNM: Florbetaben-PET detects cardiac amyloidosis
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
More News: Alzheimer's | Amyloidosis | Brain | Dementia | Neurology | Pathology | PET Scan | Study | Women